559 results on '"Valk, Peter"'
Search Results
2. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome
3. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
4. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial
5. Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations
6. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients
7. MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML
8. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML
9. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia
10. Overexpression of Oncogenic Inhibitory-ASPP (inhibitor of apoptosis stimulating protein of p53) Results in Therapy Resistance and Adverse Outcome in AML
11. Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance
12. Cohesin-STAG2 Mutations Alter Chromatin Structure and Gene Regulation in Human Acute Myeloid Leukemia
13. Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
14. Kinase Domain Mutation Testing and Clinical Outcome in a Nationwide Chronic Myeloid Leukemia Patient Population
15. High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia
16. Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database
17. Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching
18. Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
19. Transplant in older adults with AML: genomic wheat and chaff
20. Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling
21. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia
22. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia
23. PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells
24. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML
25. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers
26. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype
27. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity
28. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1
29. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
30. Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database
31. Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation
32. Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study
33. High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia
34. Pim2 cooperates with PML-RARα to induce acute myeloid leukemia in a bone marrow transplantation model
35. A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia
36. RUNX1 germline variants in RUNX1-mutant AML: how frequent?
37. Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal
38. Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status
39. AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance
40. Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C
41. Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features
42. A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene
43. Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML
44. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia
45. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia
46. Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1Mutated AML - Results of the European Harmony Alliance
47. TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia
48. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia
49. Clonal Evolution of Multiple Myeloma in Patients from Diagnosis to First Relapse, Who Were Treated in Subsequent Clinical Trials
50. Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.